Should Growth Investors Buy This Genetic Diagnostics Stock? [The Motley Fool]
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: The Motley Fool
Aside from getting the entry point right on an investment, being a growth investor arguably boils down to two key factors: picking a well-run company, and one that's operating in an industry set to experience tremendous growth.Given the increasing emphasis on early diagnosis and treatment of diseases, market research firm Global Market Insights anticipates the global genetic-testing market will grow .6% annually from $4.9 billion last year to $3.9 billion by 07. As a quality, midsize genetic-diagnostics company,Veracyte(NASDAQ:VCYTWhat makes Veracyte a great business? And should you buy the stock at its current valuation? Let's dig in to answer these questions.Image source: Getty Images.Splendid top-line growthVeracyte reported $60.4 million in revenue during the third quarter, which represents a 94% year-over-year increase. How was the company able to nearly double its revenue over the past year?The company's testing revenue surged 80% year over year to $50.9 million. This was the re
Show less
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- CareDx appoints John Hanna as president and CEO [Seeking Alpha]Seeking Alpha
- Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 [Yahoo! Finance]Yahoo! Finance
- Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024Business Wire
- Global Precision Medicine Software Markets, 2023-2024 and 2033: Rise in Personalized Healthcare and Cloud-Based Delivery Mode-Based Platforms Elevating Data Accessibility [Yahoo! Finance]Yahoo! Finance
- Veracyte, Inc. (NASDAQ: VCYT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $32.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
VCYT
Earnings
- 2/22/24 - Miss
VCYT
Sec Filings
- 4/17/24 - Form 8-K/A
- 4/2/24 - Form 4
- 4/1/24 - Form 144
- VCYT's page on the SEC website